Logo Logo
Help
Contact
Switch Language to German

Bruggen, M-C.; Valencak, J.; Stranzenbach, R.; Li, N.; Stadler, R.; Jonak, C.; Bauer, W.; Porkert, S.; Blaschke, A.; Meiss, F.; Nicolay, J. P.; Wehkamp, U.; Schlaak, M.; Nguyen, V. A.; Romani, N.; Cozzio, A.; Gayathri, N.; Dimitriou, F.; French, L. E.; Dummer, R. and Guenova, E. (2020): Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. In: Journal of the European Academy of Dermatology and Venereology, Vol. 34, No. 7: pp. 1489-1495

Full text not available from 'Open Access LMU'.

Abstract

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in the skin. We sought to provide a thorough clinical characterization and report our experience on therapeutic approaches toBPDCN. Methods In the present multicentric retrospective study, we collected allBPDCNcases occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous lymphoma working group. Results A total of 37BPDCNcases were identified and included. Almost 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in addition to skin involvement. The latter presented with various types of cutaneous lesions: nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease. Eleven patients underwent haematopoietic stem cell transplantation (HSCT;autologousHSCTn = 3, allo-HSCTn = 8). The mortality rate amongHSCTpatients was only 33.33% with a median survival time of 60.5 months. Conclusion Our study demonstrates the clinical diversity of cutaneousBPDCNmanifestations and the positive development observed after the introduction ofHSCT.

Actions (login required)

View Item View Item